{"name":"CuraGen Corporation","slug":"curagen-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CG53135-05, velafermin","genericName":"CG53135-05, velafermin","slug":"cg53135-05-velafermin","indication":"Diabetic foot ulcers","status":"phase_2"}]}],"pipeline":[{"name":"CG53135-05, velafermin","genericName":"CG53135-05, velafermin","slug":"cg53135-05-velafermin","phase":"phase_2","mechanism":"Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing.","indications":["Diabetic foot ulcers","Venous leg ulcers"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNYkFfeDlxckt0YWpqSXBzY0NWQ3VMZ3dlN1lOQ2QySmxmZUFQX1pDQ2pkV2xOQjNfaENPT3lLWFRUaVVWTmZvYnhCWUFYNUwzVWM3VGJ5T2lrcGZLY29VOURXN2pHTUJXeU4xTTJ2UmstQVZjX1RqcG1PRVhvdmNhRTI1X0Zwc0x5WHZVc2NR?oc=5","date":"2024-07-22","type":"pipeline","source":"citybiz","summary":"HOOKIPA Pharma Appoints Dr. Malte Peters as CEO - citybiz","headline":"HOOKIPA Pharma Appoints Dr. Malte Peters as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQlV6V1lUMWJUczRyUTJHeFNvdXdDNWhMdVpmbGR1OUhyaUNSajhhejQ1MEJNcVBhQU5vb1gtQ1dacElvSlVHSVlGS0c3UWlRQzRxY1F1MDR1M0FFQ0tNOHF2VjRobWFyWVlrbWNTNzJtMGw2c191NDRrZ19BeV9VZ3psOGdKU0c3VW0wbUNUM0pyejBVT0tfOFpDbDkwcXpySHZveVYwZnE3dTg?oc=5","date":"2022-08-11","type":"pipeline","source":"The Healthcare Technology Report.","summary":"The Top 25 Healthcare Technology Leaders of Connecticut for 2022 - The Healthcare Technology Report.","headline":"The Top 25 Healthcare Technology Leaders of Connecticut for 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOU2FrUDFHQXFoSkJ3djJveGx5ZVZJc1lwaXhlTmQyT1VPODRSNWdUZGtTLTU4Z3BmWnhzVk16SkxNc3I4WGE0cllPQWNGSjlLZEhZbVFrLWR6UzUteHBmOWstX2tGSjFWRWVJUkd2T2d5ZWlvSzE1VkJ1THZLUUV4aVZENDd0Zw?oc=5","date":"2006-05-30","type":"trial","source":"Contract Pharma","summary":"CuraGen Begins Velafirmin Trial - Contract Pharma","headline":"CuraGen Begins Velafirmin Trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}